Repotrectinib 40mg Cap
| Product Overview | |
| Generic Name | Repotrectinib 40mg Cap |
| Brand Name(s) | Augtyro™ |
| Form | Hard shell capsules; oral use |
| Strength | 40 mg; 160 mg |
| Therapeutic Class | Antineoplastic agent; kinase inhibitor |
| ATC Code | L01EX28 |
| Manufacturing & Regulatory | |
| Manufacturer | Bristol-Myers Squibb |
| Country | USA, UK |
| GMP Compliance | WHO-GMP, EU-GMP |
| COFEPRIS | No confirmed COFEPRIS clave found |
| Free Sale Certificate | only through BMS or an authorised distributor |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 12-18 Months |
| Storage | store below 25°C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | batch-specific CoA / Certificate of Conformance / batch release documentation from BMS |
| CTD Summary | Full CTD/eCTD Modules 2–5 remain proprietary and are not provided freely |
Description
An oral kinase inhibitor indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer
